Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

SAN FRANCISCO, Sept. 21 /PRNewswire-FirstCall/ -- Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS). At three years, XIENCE V demonstrated a 43 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS, p-value=0.003)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply). The three-year results from the SPIRIT III trial will be presented today by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"The SPIRIT III results clearly demonstrate that at three years, patients continue to benefit from having been treated with the XIENCE V stent rather than the TAXUS stent, with fewer repeat cardiac procedures and fewer heart attacks in patients who received XIENCE V," said Dr. Stone, who is also immediate past chairman of the Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III trial.

XIENCE V demonstrated an impressive low rate of very late stent thrombosis (one to three years) with no additional events between two and three years. Per protocol, XIENCE V demonstrated a 0.2 percent** very late stent thrombosis rate compared to 1.0 percent for TAXUS (p-value=0.10) at three years. Per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis, the rate of very
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... NEW YORK , Sept. 12, 2014  Pomerantz ... Laboratories, Inc. ("Impax" or the "Company")(NASDAQ: IPXL ) ... in United States District Court, District of ... on behalf of a class consisting of all persons ... 2013 and July 28, 2014, inclusive (the "Class Period").  ...
(Date:9/12/2014)... , Sept. 12, 2014 ViewRay™, a privately ... showcase its MRIdian™ (me-rid-i-an) system, the world,s first and ... Annual Meeting of the American Society for Radiation ... San Francisco . With ViewRay,s recent announcements ... at Siteman Cancer Center and the first patient treated ...
(Date:9/12/2014)... Sept. 12, 2014 Research and Markets  has ... MRI & Ultrasound) Market & Forecast - Worldwide" report ... most common cancer among women in both the developed and ... digit Billion US$ for 2013. United States ... China is expected to maintain its ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Impax Laboratories, Inc. and Certain Officers - IPXL 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Impax Laboratories, Inc. and Certain Officers - IPXL 3ViewRay to Showcase World's Only MRI-Guided Radiation Therapy System In Clinical Use at Largest Radiation Oncology Meeting 2ViewRay to Showcase World's Only MRI-Guided Radiation Therapy System In Clinical Use at Largest Radiation Oncology Meeting 3Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast - Worldwide 2Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast - Worldwide 3Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast - Worldwide 4
... Feb. 21, 2012  Celling Biosciences announces a sponsorship of the ... at Bridgewaters New York in New York City. The Stem ... leaders in regenerative medicine to network and promote next generation ... more than 30 thought leaders in stem cell therapy including ...
... February 21, 2012 New collaboration ... analytics tools into the physician workflow through PatientKeeper ... provider of scientific, technical and medical information products ... provider of physician healthcare information systems, today announced ...
Cached Medicine Technology:Celling Biosciences Sponsors 7th Annual Stem Cell Summit 2Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 2Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 3Elsevier Integrates its Clinical Decision Support Solutions Into PatientKeeper CPOE 4
(Date:9/15/2014)... San Diego, CA (PRWEB) September 15, 2014 ... website daily regarding all the latest information from the ... Following a previous announcement from the FDA, the Agency ... Labs (aka NuVision Pharmacy) the immediate recall ... on the market that are not expired due to ...
(Date:9/15/2014)... Lauderdale, FL (PRWEB) September 15, 2014 (PRWEB) September 15, ... and what’s not; what the startup business requirements are ... market the new business. , Speakers include industry professionals, ... Harborside Health Center in Oakland,CA and cannabis business ... CO , who are already successfully running legal marijuana ...
(Date:9/15/2014)... Recently, Top10BestSEOHosting.com has compared many professional ... http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), IX Web Hosting and GoDaddy are ... “These companies have outperformed other competitors in hosting ... we call them the Best VPS Hosting supplier. ... best web hosting to enjoy the power of ...
(Date:9/14/2014)... (PRWEB) September 15, 2014 Skin becomes dryer ... like sun damage and not moisturizing properly. However, there are ... has been cared for. , Two main reasons this occurs: ... of hyaluronic acid in the skin , During the aging ... of these are responsible for important moisture retention and radiance ...
(Date:9/14/2014)... St. Louis, MO (PRWEB) September 14, 2014 ... events can now use the Quotes Pros website to ... portal that was constructed this year at http://quotespros.com/life-insurance.html ... , The insurance company partners that are preparing ... this year are located in most U.S. states. As ...
Breaking Medicine News(10 mins):Health News:FDA Requests Recall of Sterile Drug Products by Downing Labs (aka NuVision Pharmacy): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:How to Start And Run a Successful Legal Marijuana Business 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 2Health News:2 Reasons Skin Becomes Dryer with Age and What To Do About It, From Sublime Beauty® 3Health News:Quotes for Life Insurance Now Offered at New Consumer Portal Online 2
... in French . , In addition to their ... reality that few pharmaceutical companies will ever be able to ... new treatments will never be recovered from such a small ... U.S. Food and Drug Administration,s "Orphan Drug Designation" offers a ...
... early-stage syphilis, researchers have found that antibiotic pills (azithromycin) ... syphilis. The study was supported by the National Institute ... Institutes of Health. Edward W. Hook, III, M.D., ... trial. Between June 2000 and March 2007, HIV-negative volunteers ...
... who refuse surgery for prostate cancer and instead opt ... treatment have a significantly worse long-term survival rate ... at Henry Ford Hospital in Detroit. The study ... prostate cancer had a 10-year overall survival rate of ...
... ... providing support and information to midwifery professionals and parents, is the first to ... ... based company providing support and information to midwifery professionals and parents, is the first ...
... fat, with few fruits and vegetables , TUESDAY, June 1 (HealthDay ... you,ll end up with huge amounts of fat and sugar but ... finding of a new study that analyzes what would happen if ... advertised on the tube. , Researchers found that such a ...
... Shutting down sperm production has proved complicated, experts say ... a century, women have had access to birth control ... one has come up with an equivalent product for ... dramatically reduce sperm production. , Efforts are underway, however. ...
Cached Medicine News:Health News:McGill's 'Orphan Drug' research offers hope 2Health News:Patients who refuse prostate cancer surgery have worse long-term survival 2Health News:Pregnancy, Birth and Beyond Launches the Aquaborn Eco Birth Pool Range in Australia 2Health News:Pregnancy, Birth and Beyond Launches the Aquaborn Eco Birth Pool Range in Australia 3Health News:Male 'Pill' Still a Ways Off 2Health News:Male 'Pill' Still a Ways Off 3
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Very concise book answering the question: "I've got a diagnosis, which drugs do I use?". All 15 chapters written by highly skilled US specialists...
Make better prescribing decisions with this drug interaction analyzer containing over 3,000 brand names with generic equivalents....
Davis's Drug Guide for Nurses - now with over 760 Integrated Calculators - combines the most comprehensive, up-to-date and practical drug resource with built in drug dosing calculation tools for most...
Medicine Products: